Evidence map›Paper›PMID 30655375›Full record

Trial reportHaematologica2019

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Thorben Mährle, Nuray Akyüz, Pim Fuchs, Nicola Bonzanni, Donjete Simnica, Ulrich Germing, Anne Marie Asemissen, Johann Christoph Jann, Florian Nolte, Wolf-Karsten Hofmann and 2 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Thorben MährleDepartment of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nuray AkyüzDepartment of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pim FuchsENPICOM, 's-Hertogenbosch, the Netherlands.
Nicola BonzanniENPICOM, 's-Hertogenbosch, the Netherlands.
Donjete SimnicaDepartment of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ulrich GermingDepartment of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University Düsseldorf, Germany.
Anne Marie AsemissenDepartment of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johann Christoph JannDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
Florian NolteDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
Daniel NowakDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
Mascha BinderDepartment of Oncology and Hematology, BMT with Pneumology section, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany mascha.binder@uk-halle.de.
ENPICOM (Netherlands) · NLHeidelberg University · DEUniversität Hamburg · DEUniversity Cancer Center Hamburg · DEHeinrich Heine University Düsseldorf · DEUniversity Hospital Heidelberg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity Medical Centre Mannheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In myelodysplastic syndromes with a partial deletion of the long arm of chromosome 5, del(5q), lenalidomide is believed to reverse anergic T-cell immunity in the bone marrow resulting in suppression of the del(5q) clone. In this study we used next-generation sequencing of immunoglobulin heavy chain (

Indexed as

AgedAntigens, NeoplasmAntineoplastic AgentsBone MarrowCase-Control StudiesChromosome DeletionChromosomes, Human, Pair 5FemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansLenalidomideMaleMiddle AgedMyelodysplastic SyndromesPrognosisAntigens, NeoplasmAntineoplastic AgentsLenalidomide

Identifiers

PMID30655375
PMCPMC6601099
OpenAlexW2910533485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.